. 2020 Jan 27;64(2):e01541-19. doi: 10.1128/AAC.01541-19

TABLE 1.

MICs and susceptibility of 414 Pseudomonas aeruginosa isolates from cystic fibrosis patients

Drug	Value for the isolate group or type (mg/liter)										Susceptibility (%) by standard (n = 414)^a
	All strains (n = 414)		Pediatric (n = 111)		Adult (n = 288)		Mucoid (n = 112)		Small-colony variant (n = 63)		EUCAST			CLSI
	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀	S	I	R	S	I	R
Murepavadin	0.12	2	0.12	1	0.25	4	0.12	2	0.25	8	ND	ND	ND	ND	ND	ND
Cefepime	4	32	4	16	8	64	8	32	8	>128	75		25	75	11	14
Ceftazidime	2	64	2	8	2	128	2	8	2	128	80		20	80	4	11
Ceftazidime-avibactam	2	8	2	4	2	8	1	8	2	8	93		7	93		7
Ceftolozane-tazobactam	1	2	0.5	2	1	4	1	2	1	4	95		5	95	1	3
Piperacillin-tazobactam	4	128	4	32	4	>256	2	128	2	>256	81		19	81	7	12
Meropenem	0.25	16	0.25	4	0.5	16	0.5	16	0.5	16	76	12	12	76	6	18
Imipenem	2	32	2	16	2	32	2	32	1	32	68		32	59	8	32
Aztreonam	8	128	8	32	4	256	2	64	2	>256	77		23	62	14	23
Ciprofloxacin	1	8	0.5	4	2	8	1	8	2	16	39		61	53	17	30
Gentamicin	4	64	4	32	8	64	4	16	8	>128	53		47	53	17	30
Tobramycin	1	16	0.5	8	2	16	1	4	2	64	84		16	84	5	12
Amikacin	16	64	8	64	16	128	16	64	16	>128	47	21	32	68	14	18
Colistin	1	2	1	2	1	2	0.5	1	1	4	93		7	93	3	4

S, susceptible; I, intermediately susceptible; R, resistant; ND, no breakpoint defined.